Principal Financial Group Inc Biocryst Pharmaceuticals Inc Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$6.41 - $8.69 $2.41 Million - $3.27 Million	375,890 Added 1058.13%	411,414 $3.13 Million
Q2 2024 Jul 29, 2024	SELL	$4.13 - $6.79 $52,413 - $86,171	-12,691 Reduced 26.32%	35,524 $219,000
Q1 2024 Apr 29, 2024	BUY	$4.89 - $7.65 $1,056 - $1,652	216 Added 0.45%	48,215 $244,000
Q4 2023 Feb 07, 2024	SELL	$4.98 - $6.77 $3,381 - $4,596	-679 Reduced 1.39%	47,999 $287,000
Q3 2023 Nov 02, 2023	BUY	$6.71 - $7.92 $7,515 - $8,870	1,120 Added 2.36%	48,678 $344,000
Q2 2023 Aug 07, 2023	BUY	$6.96 - $8.81 $2,456 - $3,109	353 Added 0.75%	47,558 $334,000
Q1 2023 May 09, 2023	BUY	$7.94 - $11.84 $3,048 - $4,546	384 Added 0.82%	47,205 $393,000
Q4 2022 Feb 09, 2023	SELL	$10.5 - $14.2 $586,372 - $792,999	-55,845 Reduced 54.39%	46,821 $537,000
Q3 2022 Nov 09, 2022	SELL	$10.79 - $14.81 $1.04 Million - $1.43 Million	-96,743 Reduced 48.51%	102,666 $1.29 Million
Q2 2022 Aug 10, 2022	BUY	$7.89 - $17.88 $1.28 Million - $2.9 Million	162,417 Added 439.06%	199,409 $2.11 Million
Q1 2022 May 09, 2022	SELL	$11.56 - $19.76 $17,444 - $29,817	-1,509 Reduced 3.92%	36,992 $601,000
Q4 2021 Feb 09, 2022	SELL	$11.18 - $15.46 $167,834 - $232,085	-15,012 Reduced 28.05%	38,501 $534,000
Q3 2021 Nov 09, 2021	SELL	$14.21 - $17.65 $121,793 - $151,278	-8,571 Reduced 13.81%	53,513 $769,000
Q2 2021 Aug 10, 2021	SELL	$9.5 - $17.24 $101,241 - $183,726	-10,657 Reduced 14.65%	62,084 $981,000
Q1 2021 May 10, 2021	SELL	$7.37 - $13.61 $15,027 - $27,750	-2,039 Reduced 2.73%	72,741 $740,000
Q4 2020 Feb 08, 2021	BUY	$3.37 - $8.61 $66,779 - $170,615	19,816 Added 36.05%	74,780 $557,000
Q3 2020 Nov 06, 2020	SELL	$3.43 - $5.53 $5,947 - $9,589	-1,734 Reduced 3.06%	54,964 $189,000
Q2 2020 Aug 05, 2020	BUY	$1.9 - $5.61 $45,265 - $133,652	23,824 Added 72.47%	56,698 $270,000
Q1 2020 May 12, 2020	BUY	$1.6 - $4.11 $2,254 - $5,790	1,409 Added 4.48%	32,874 $66,000
Q4 2019 Feb 05, 2020	SELL	$1.59 - $3.45 $2,669 - $5,792	-1,679 Reduced 5.07%	31,465 $109,000
Q3 2019 Nov 13, 2019	BUY	$2.5 - $3.73 $8,477 - $12,648	3,391 Added 11.4%	33,144 $95,000
Q2 2019 Aug 12, 2019	SELL	$2.91 - $9.15 $3,736 - $11,748	-1,284 Reduced 4.14%	29,753 $113,000
Q1 2019 May 10, 2019	BUY	$7.38 - $9.72 $6,324 - $8,330	857 Added 2.84%	31,037 $253,000
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $80,724 - $119,040	12,400 Added 69.74%	30,180 $244,000
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $61,713 - $89,328	-11,180 Reduced 38.6%	17,780 $136,000
Q2 2018 Aug 13, 2018	BUY	$4.6 - $6.52 $6,817 - $9,662	1,482 Added 5.39%	28,960 $0
Q1 2018 May 14, 2018	BUY	$4.35 - $5.82 $9,939 - $13,298	2,285 Added 9.07%	27,478 $131,000
Q4 2017 Feb 13, 2018	BUY	$4.16 - $5.33 $54,720 - $70,110	13,154 Added 109.26%	25,193 $124,000
Q3 2017 Nov 02, 2017	BUY	$4.1 - $5.97 $49,359 - $71,872	12,039	12,039 $63,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

Vanguard Group Inc Valley Forge, PA

20.3M
Shares

$154 Million
0.0% of portfolio
Black Rock Inc. New York, NY

20M
Shares

$151 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

11.9M
Shares

$89.8 Million
1.36% of portfolio
Kynam Capital Management, LP Princeton, NJ

9.09M
Shares

$68.8 Million
5.66% of portfolio
State Street Corp Boston, MA

8.85M
Shares

$67 Million
0.0% of portfolio

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account